The original NHS, NICE, charity and research pages on this topic, with our summary of each.
NHS
Web page
Aug 2026
For patients
The NHS medicine guide to adalimumab, listing brands such as Amgevita, Humira, Imraldi and Yuflyma. It explains that it treats autoimmune conditions including Crohn's disease, is usually started by a specialist after other medicines have not worked, and needs regular blood tests.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
autoimmune condition
biosimilar
NHS England
Web page
Patients and professionals
NHS England's page on biosimilars: biological medicines shown to have no meaningful differences in quality, safety or effectiveness from the original brand. It explains why the NHS encourages their use, that switching between the original and a biosimilar is now accepted practice, and how savings are reinvested.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biosimilar
originator medicine
switching
NHS Lothian
Web page
Dec 2020
Patients and professionals
NHS Lothian's IBD page on monitoring medicines. It explains that people on infliximab or adalimumab have their drug level checked some weeks after starting and then at least yearly, with anti-drug antibodies tested if the level is low.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
drug level
anti-drug antibodies
anti-TNF
shared care
Crohn's & Colitis UK
Guide
Dec 2025
For patients
A guide to guselkumab (Tremfya), an IL-23 blocking medicine. The first three doses can be a drip or an injection, after which it is injected under the skin; the page covers vaccines and side effects.
Topics
Biologics and newer medicines
Jargon explained
IL-23
interleukin inhibitor
Crohn's & Colitis UK
Guide
Sep 2024
For patients
A guide to adalimumab, an anti-TNF biologic you inject under your skin with a pen or syringe. It explains that Humira was the first brand and Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma are biosimilars, and that blood tests may check drug and antibody levels.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
biosimilar
antibodies
subcutaneous injection
Crohn's & Colitis UK
Guide
Jul 2024
For patients
A guide to mirikizumab (Omvoh), a biologic that blocks the IL-23 protein. It explains the starting doses by drip followed by injections under the skin if it works, vaccine advice, and side effects.
Topics
Biologics and newer medicines
Jargon explained
IL-23
interleukin inhibitor
non-live vaccine
Crohn's & Colitis UK
Guide
Jun 2024
For patients
A guide to infliximab, an anti-TNF biologic given by drip or as an injection under the skin. It lists the original brand Remicade and biosimilars such as Remsima, Inflectra, Flixabi and Zessly, and explains checks before starting, that your team may measure drug and antibody levels in your blood, and possible side effects.
Topics
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
infusion
subcutaneous
biosimilar
drug levels
antibodies
Crohn's & Colitis UK
Guide
Jul 2023
For patients
A guide to risankizumab (Skyrizi), a biologic that blocks the IL-23 protein involved in inflammation. You start with a few drips, then have regular injections under the skin; the page explains trial results and side effects.
Topics
Biologics and newer medicines
Jargon explained
IL-23
interleukin
biologic
Crohn's & Colitis UK
Guide
Jul 2023
For patients
An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.
Topics
Biologics and newer medicines
Medicines
Jargon explained
biologic
biosimilar
anti-TNF
IL-23 inhibitor
JAK inhibitor
advanced therapy
Crohn's & Colitis UK
Guide
May 2023
For patients
A guide to vedolizumab (Entyvio), which starts as a drip into a vein and may later be switched to injections under the skin. It covers how it works on the gut, trial results and side effects.
Topics
Biologics and newer medicines
Jargon explained
integrin
intravenous infusion
subcutaneous injection
Crohn's & Colitis UK
Guide
For patients
A guide to ustekinumab, an interleukin inhibitor that blocks IL-12 and IL-23. Stelara was the first brand and several biosimilars now exist. The first dose is a drip, then injections under the skin; the page covers trial results and side effects.
Topics
Biologics and newer medicines
Jargon explained
interleukin inhibitor
IL-12
IL-23
biosimilar
Crohn's & Colitis UK
Guide
For patients
A guide to upadacitinib (Rinvoq), a tablet that belongs to the JAK inhibitor group of targeted medicines. It explains how blocking JAK proteins calms the immune response, what trials showed, and the side effects and safety checks involved.
Topics
Medicines
Biologics and newer medicines
Jargon explained
JAK inhibitor
Janus kinase
targeted medicine
small molecule
Crohn's & Colitis UK
Guide
For patients
Explains the basics behind IBD medicines: active and inactive ingredients, brand and generic names, and what biosimilars are. It uses infliximab as an example, explaining that biosimilars meet strict standards and you may sometimes be moved to a different one.
Topics
Medicines
Biologics and newer medicines
Jargon explained
biosimilar
originator
generic
Crohn's & Colitis UK
Guide
Jan 2026
For patients
Explains why fistulas are more common in Crohn's, the different types (perianal is the most common), how they are found, including examination under anaesthetic and MRI, and treatment with medicines, setons and other surgery. It describes what living with a seton is like and gives clear urgent-help advice: contact your GP or 111 for fever, pain and pus, and 999 or A&E for possible sepsis.
Topics
Around the bottom (perianal)
Complications
Surgery
Urgent help
Biologics and newer medicines
Jargon explained
fistula
perianal fistula
seton
examination under anaesthetic
perianal abscess
sepsis
fistulotomy
anti-tnf
perianal
metronidazole
ciprofloxacin
Crohn's & Colitis UK
Guide
Oct 2023
For patients
Practical ways to lower the risks of medicines that suppress the immune system. You should not have live vaccines while on an immunosuppressant, but non-live vaccines such as the injected flu jab, COVID-19, Shingrix shingles and pneumococcal vaccines are safe. It explains checks for chickenpox immunity, the slightly raised risk of some cancers, especially skin cancer, and sun safety, plus food hygiene and travel precautions.
Topics
Immunosuppressants
Vaccinations and infections
Cancer risk and screening
Travel
Biologics and newer medicines
Jargon explained
immunosuppressant
live vaccine
non-live vaccine
Shingrix
pneumococcal vaccine
JAK inhibitor
anti-TNF
Cochrane
Systematic review
Jun 2026
Patients and professionals
An NIHR-funded Cochrane review that compares all the biologic and newer drugs for Crohn's at once, even where they were never tested against each other directly. Many, including adalimumab, risankizumab, guselkumab, upadacitinib and vedolizumab, were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors say more head-to-head trials, more focus on bowel healing, and better long-term safety data are needed.
Topics
Biologics and newer medicines
Research
Jargon explained
network meta-analysis
relative risk
number needed to treat
biosimilar
Cochrane
Systematic review
May 2025
Patients and professionals
Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.
Topics
Biologics and newer medicines
Jargon explained
IL-12/23
induction
certainty of evidence
Cochrane (via PMC)
Systematic review
Nov 2023
Patients and professionals
A Cochrane review finding infliximab combined with azathioprine or mercaptopurine probably works better than either thiopurine alone for bringing Crohn's into remission. Infliximab may work similarly to its CT-P13 biosimilar.
Topics
Biologics and newer medicines
Research
Jargon explained
combination therapy
purine analogue
biosimilar
CT-P13
Cochrane
Systematic review
Jul 2023
Patients and professionals
Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.
Topics
Biologics and newer medicines
Research
Jargon explained
high-certainty evidence
induction
maintenance
integrin
Cochrane
Systematic review
May 2020
Patients and professionals
Cochrane concluded that adalimumab works for keeping Crohn's in remission, including in people who had already tried another anti-TNF drug. Whether it helps after bowel surgery is still unclear.
Topics
Biologics and newer medicines
Jargon explained
anti-TNF
maintenance
quiescent
Cochrane (via PMC)
Systematic review
Nov 2019
Patients and professionals
A Cochrane review with high-certainty evidence that adalimumab works better than placebo for bringing moderate to severe Crohn's into remission. Long-term safety needed more study.
Topics
Biologics and newer medicines
Research
Jargon explained
induction
placebo
anti-TNF
New England Journal of Medicine
Study
Jul 2024
Patients and professionals
A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.
Topics
Biologics and newer medicines
Research
Jargon explained
non-inferiority
endoscopic remission
anti-TNF
The Lancet Gastroenterology & Hepatology
Study
May 2024
Patients and professionals
A large UK-led trial of 386 newly diagnosed adults. Starting straight away with infliximab plus an immunosuppressant ('top-down') kept 79% in remission without steroids or surgery for a year, compared with 15% using the usual 'step-up' approach of trying milder drugs first. There were also fewer flares, serious side effects and operations. A blood test meant to predict who needed strong treatment did not help. Free to read in full.
Topics
Biologics and newer medicines
Research
About Crohn's disease
Jargon explained
top-down treatment
step-up treatment
biomarker
steroid-free remission
top-down
step-up
immunomodulator
randomised controlled trial
The Lancet
Study
Jun 2022
Patients and professionals
One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.
Topics
Biologics and newer medicines
Research
Jargon explained
head-to-head trial
biologic-naive
confidence interval
The Lancet
Study
May 2022
Patients and professionals
Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.
Topics
Biologics and newer medicines
Jargon explained
induction
phase 3 trial
endoscopic response
New England Journal of Medicine
Study
Nov 2016
Patients and professionals
The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.
Topics
Biologics and newer medicines
Jargon explained
induction
maintenance
IL-12/23
placebo
New England Journal of Medicine
Study
Aug 2013
Patients and professionals
The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.
Topics
Biologics and newer medicines
Jargon explained
integrin
induction
maintenance
serious adverse event
New England Journal of Medicine
Study
Apr 2010
Patients and professionals
A landmark trial of 508 adults with moderate to severe Crohn's who had never had immunosuppressants or biologics. Infliximab and azathioprine together worked best: about 57% were in remission without steroids at 26 weeks, against 44% on infliximab alone and 30% on azathioprine alone. This is why many people starting infliximab are offered a second 'helper' drug alongside it.
Topics
Biologics and newer medicines
Immunosuppressants
Research
Jargon explained
combination therapy
steroid-free remission
mucosal healing
randomised controlled trial
Gastroenterology
Study
Jan 2007
Patients and professionals
The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.
Topics
Biologics and newer medicines
Jargon explained
maintenance
remission
CDAI
placebo
The Lancet
Study
May 2002
Patients and professionals
This trial asked whether people who improve after a first dose of infliximab should keep having it. Those given regular doses every 8 weeks were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those who stopped. Serious infections were no more common. It set the pattern of regular, ongoing infliximab treatment.
Topics
Biologics and newer medicines
Research
Jargon explained
maintenance therapy
remission
placebo
The Lancet Gastroenterology & Hepatology
Study
Oct 2020
Patients and professionals
A longer look back at the people in the LIR!C trial. It supported keyhole removal of the end of the small bowel as a real option for people with short, mainly inflamed (not narrowed) disease when standard medicines have not worked. In both groups, adding an immunosuppressant was linked to the benefit lasting longer.
Topics
Surgery
Biologics and newer medicines
Jargon explained
retrospective
hazard ratio
immunomodulator
The Lancet
Study
Dec 2017
Patients and professionals
CALM compared deciding treatment on symptoms alone with 'tight control', where treatment was stepped up if blood or poo tests (CRP and faecal calprotectin) showed inflammation even when people felt fine. After 48 weeks, 46% in the tight control group had a healed bowel lining compared with 30% in the symptom-only group. It is a cornerstone of the 'treat to target' approach.
Topics
Monitoring
Biologics and newer medicines
Research
Jargon explained
tight control
faecal calprotectin
CRP
mucosal healing
treat to target
The Lancet Gastroenterology & Hepatology
Study
Nov 2017
Patients and professionals
A Dutch and UK trial in adults whose Crohn's affected a short stretch (under 40 cm) at the end of the small bowel and had not settled with standard medicines. Keyhole surgery to remove that section was compared with infliximab, looking mainly at quality of life at one year. The authors concluded surgery is a reasonable alternative to infliximab for this group. Over about four years, 37% of the infliximab group ended up having surgery anyway.
Topics
Surgery
Biologics and newer medicines
Research
Jargon explained
laparoscopic
ileocaecal resection
terminal ileum
quality of life
terminal ileitis
Gastroenterology
Study
Mar 2007
Patients and professionals
The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.
Topics
Children and young people
Biologics and newer medicines
Jargon explained
induction
maintenance
clinical response
PCDAI
New England Journal of Medicine
Study
Feb 2004
Patients and professionals
A trial in people with Crohn's fistulas (abnormal tunnels, often around the anus) who had responded to infliximab. Carrying on with infliximab every 8 weeks kept people well for much longer than switching to a dummy drug. At one year, 36% on infliximab had no draining fistulas, against 19% on placebo.
Topics
Around the bottom (perianal)
Biologics and newer medicines
Jargon explained
fistula
fistulizing disease
placebo
NICE
Guideline
Aug 2025
For professionals
NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
conventional treatment
NICE
Guideline
Jul 2025
For professionals
NICE's appraisal allowing mirikizumab (Omvoh) to be used for adults with moderate to severe Crohn's disease after a previous biologic has not worked or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
NICE
Guideline
May 2023
For professionals
NICE's appraisal recommending risankizumab (Skyrizi) for people aged 16 and over with moderate to severe Crohn's disease after a previous biologic has failed or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Biologics and newer medicines
Medicines
Jargon explained
IL-23 inhibitor
TNF-alpha inhibitor
biological treatment
NICE
Guideline
Jul 2017
For professionals
NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.
Topics
Biologics and newer medicines
Medicines
Jargon explained
interleukin inhibitor
TNF-alpha inhibitor
biological therapy
NICE
Guideline
Aug 2015
For professionals
NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.
Topics
Biologics and newer medicines
Medicines
Jargon explained
anti-TNF
TNF-alpha inhibitor
patient access scheme
moderately to severely active
NICE
Guideline
May 2010
For professionals
NICE's appraisal approving infliximab and adalimumab on the NHS for adults with severe active Crohn's disease when standard treatments such as steroids or immunosuppressants have not worked or cannot be used. It applies to biosimilar versions too, and says treatment should be reviewed at least every 12 months to decide whether to continue.
Topics
Biologics and newer medicines
Medicines
Jargon explained
anti-TNF
biosimilar
conventional therapy
severe active Crohn's disease
European Crohn's and Colitis Organisation (J Crohns Colitis)
Guideline
Oct 2024
For professionals
Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.
Topics
Medicines
Biologics and newer medicines
Immunosuppressants
Around the bottom (perianal)
Jargon explained
biologic
immunomodulator
induction
maintenance
de-escalation
perianal fistula
GRADE
NICE
Guideline
Jun 2023
For professionals
NICE's appraisal recommending upadacitinib (Rinvoq), a tablet, for adults with moderate to severe Crohn's disease after a biologic has not worked, stopped working or was not tolerated, or when anti-TNF medicines are unsuitable.
Topics
Medicines
Biologics and newer medicines
Jargon explained
JAK inhibitor
small molecule
TNF-alpha inhibitor
American Gastroenterological Association (Gastroenterology)
Guideline
Jun 2021
For professionals
The American Gastroenterological Association's guideline on medicines for moderate to severe Crohn's, including fistulas around the anus. It rates the strength of evidence behind each drug option. It is American, so some drug choices and approvals differ from the NHS, but it is free to read in full and widely cited.
Topics
Medicines
Biologics and newer medicines
Around the bottom (perianal)
Jargon explained
luminal
perianal fistulizing
certainty of evidence
NICE
Guideline
Feb 2016
For professionals
NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.
Topics
Monitoring
Biologics and newer medicines
Jargon explained
therapeutic drug monitoring
drug level
anti-drug antibodies
ELISA
anti-TNF
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Aug 2026
For professionals
The newest European guideline for children with Crohn's, agreed by 27 experts. Children at high risk of a difficult course should start an anti-TNF biologic first, with blood-level checks of the drug. For lower-risk children, a liquid-only diet (EEN) or the Crohn's Disease Exclusion Diet with partial liquid feeds are the preferred first treatments. Long-term goals include a healed bowel lining, normal growth and a good quality of life.
Topics
Children and young people
Diet and nutrition
Biologics and newer medicines
Monitoring
Jargon explained
anti-TNF
therapeutic drug monitoring
exclusive enteral nutrition
endoscopic remission
Gut
Guideline
Sep 2014
For professionals
An international expert consensus on perianal fistulas in Crohn's. Key points: combine more than one test for an accurate picture, always drain infection before starting immune-suppressing treatment, anti-TNF medicines are the main treatment, and definitive surgical repair is only considered when the rectum is not inflamed.
Topics
Around the bottom (perianal)
Surgery
Biologics and newer medicines
Jargon explained
perianal fistula
anti-tnf
proctitis
seton
ECCO and ESPGHAN (J Crohns Colitis)
Guideline
Feb 2021
For professionals
European children's gut specialists agreed how to treat Crohn's in children and teenagers. A key message is to spot early the children most likely to have a difficult course, such as those with disease around the bottom or narrowing or penetrating disease, so stronger treatment can start early and limit long-term bowel damage.
Topics
Children and young people
Medicines
Diet and nutrition
Biologics and newer medicines
Jargon explained
paediatric
penetrating disease
stricturing disease
exclusive enteral nutrition
anti-TNF
immunomodulator
therapeutic drug monitoring